Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,125.71
(
0.87%
)
US TECH 100
26,158.07
(
1.49%
)
Dow Jones
49,456.08
(
0.02%
)
Brent Oil
97.23
(
2.33%
)
Bitcoin
78,908.85
(
3.38%
)
News Focus
News Focus
Post# of 257437
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225356

Wednesday, 03/11/2020 10:45:34 AM

Wednesday, March 11, 2020 10:45:34 AM

Post# of 257437
FDA approves Opdivo/Yervoy in second-line HCC (following Nexavar in the first line):

https://www.businesswire.com/news/home/20200311005141/en

This is an accelerated approval based on ORR and DoR in the CHECKMATE-40 study—the same study that led to FDA accelerated approval of Opdivo monotherapy in second-line HCC in Sep 2017 (https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibbs-opdivo-nivolumab-receives-fda-approval-t ).

p.s. In first-line HCC, Opdivo monotherapy failed to best Nexavar in the CHECKMATE-459 study (#msg-149555601).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today